Janet Grove

Janet Grove stands at the helm of the Canadian life sciences and healthcare sector, leveraging her rich background in corporate development and legal roles. Her journey has equipped her with an acute expertise in navigating the complexities of mergers, acquisitions, and the forging of intricate commercial partnerships. Grove's prowess extends across a spectrum of fields including IT, health sciences, telecommunications, and clean technologies, making her a go-to advisor for a diverse clientele seeking to innovate, commercialize, and secure technology through strategic arrangements.

Her portfolio boasts an impressive array of clients, from nascent tech and biotech ventures to established corporations, academic bodies, healthcare entities, and research institutes across Canada. Known for her sagacity in some of British Columbia's landmark technology deals, Grove's nuanced grasp of transactional intricacies is highly valued. Her stint as an in-house counsel at a globally recognized biopharmaceutical firm, listed on both TSX and NASDAQ, has fine-tuned her appreciation for the evolving demands of corporate counsel roles, enhancing her support to clients in these capacities. Here, she contributed as vice-president and corporate counsel, guiding the board and management through a labyrinth of business, technological, and legal challenges.

Previously steering the Vancouver office as managing partner, Grove's academic credentials are just as formidable, with a Directors College certification from Stanford Law School, an LL.B. from the University of Victoria, and a B.Sc. (Hons.) in Biochemistry from the same institution.

Her legal acumen spans a broad spectrum of services, encompassing communications, media, entertainment, life sciences, pharmaceuticals, and emerging technologies. Her industry expertise is particularly noted in life sciences, healthcare, and technology sectors.

Grove's notable representations include advising Vanrx Pharmasystems Inc. through its acquisition by Danaher Corporation, guiding Evonik Corporation in its acquisitions, and assisting ImmunoPrecise Antibodies Ltd. with its NASDAQ listing and public offering. She has played a pivotal role in the financing of Zucara Therapeutics Inc. and has been instrumental in numerous biotech licensing deals and research collaborations.

Her contributions to the Accel-Rx Health Sciences Accelerator Society underscore her commitment to fostering health sciences innovation in Canada. Moreover, her involvement in significant transactions for Energizer Holdings, Inc., including acquisitions and sales, showcases her proficiency in navigating complex M&A landscapes. As Canadian counsel for Vivonet Inc., QLT Inc., and the AFCC Automotive Fuel Cell Cooperative Corp., Grove has demonstrated her versatile legal expertise across various industries, underscoring her invaluable role in shaping the future of technology and healthcare.